Why the FDA Should Prohibit the Direct Advertising of Prescription Drugs to the Consumer

Limiting DTC drug ads

The moratorium on direct-to-consumer (DTC) prescription drug ads protected patients because it enabled health care practitioners and other professionals to make educated, informed decisions about potentially harmful substances rather than the consumer relying on materials designed exclusively at sales, promotion, and marketing.

DTC drug ads should be again limited by the FDA because the advertisements are potentially misleading, causing consumers to request drugs that they have seen on television or in print ads. These ads can offer what are essentially "miracle" cures, while downplaying potential harmful side effects or by failing to mention other alternatives. "Most direct-to-consumer advertising does not warn patients of drug-drug interactions," ("Direct to Consumer Advertising"). Moreover, many patients might stop taking the medication they are currently on because they see an ad for something else.

The FDA should be dedicated to promoting public health and safety. If prescription drug advertisements interfere at all with this primary objective then the DTC approach to the pharmaceutical industry must be more carefully examined and reconsidered.

DTC prescription drug ads interfere with spending that could be channeled into research and development of new products; an exorbitant amount of money is spent on drug advertisements.